These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30539165)

  • 1. Delafloxacin meglumine for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
    Kaul G; Kapoor E; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Nov; 54(11):657-666. PubMed ID: 30539165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone.
    Cho JC; Crotty MP; White BP; Worley MV
    Pharmacotherapy; 2018 Jan; 38(1):108-121. PubMed ID: 29059465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.
    Ocheretyaner ER; Park TE
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):523-530. PubMed ID: 29911455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delafloxacin: First Global Approval.
    Markham A
    Drugs; 2017 Sep; 77(13):1481-1486. PubMed ID: 28748399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering.
    Bassetti M; Righi E; Pecori D; Tillotson G
    Future Microbiol; 2018 Aug; 13():1081-1094. PubMed ID: 29764190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.
    O'Riordan W; McManus A; Teras J; Poromanski I; Cruz-Saldariagga M; Quintas M; Lawrence L; Liang S; Cammarata S;
    Clin Infect Dis; 2018 Aug; 67(5):657-666. PubMed ID: 29518178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Scott LJ
    Drugs; 2020 Aug; 80(12):1247-1258. PubMed ID: 32666425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delafloxacin for the treatment of respiratory and skin infections.
    Bassetti M; Della Siega P; Pecori D; Scarparo C; Righi E
    Expert Opin Investig Drugs; 2015 Mar; 24(3):433-42. PubMed ID: 25604710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections.
    Bassetti M; Pecori D; Cojutti P; Righi E; Pea F
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1193-1200. PubMed ID: 28988505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical review of delafloxacin: a novel anionic fluoroquinolone.
    Mogle BT; Steele JM; Thomas SJ; Bohan KH; Kufel WD
    J Antimicrob Chemother; 2018 Jun; 73(6):1439-1451. PubMed ID: 29425340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
    Giordano PA; Pogue JM; Cammarata S
    Clin Infect Dis; 2019 Apr; 68(Suppl 3):S223-S232. PubMed ID: 30957167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delafloxacin (Baxdela)--a new fluoroquinolone antibiotic.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):49-51. PubMed ID: 29635263
    [No Abstract]   [Full Text] [Related]  

  • 13.
    McCurdy S; Lawrence L; Quintas M; Woosley L; Flamm R; Tseng C; Cammarata S
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014-2019).
    Shortridge D; Pfaller MA; Streit JM; Flamm RK
    J Glob Antimicrob Resist; 2020 Dec; 23():278-283. PubMed ID: 33068780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin.
    Shiu J; Ting G; Kiang TK
    Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):305-317. PubMed ID: 30324277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
    Corey GR; McKinnell JA; Rybak MJ
    Clin Infect Dis; 2019 Apr; 68(Suppl 3):S191-S192. PubMed ID: 30957163
    [No Abstract]   [Full Text] [Related]  

  • 17. Delafloxacin: A Review in Community-Acquired Pneumonia.
    Lee A; Lamb YN; Shirley M
    Drugs; 2022 Jun; 82(8):913-923. PubMed ID: 35708893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levonadifloxacin arginine salt to treat acute bacterial skin and skin structure infection due to S. aureus including MRSA.
    Saxena D; Kaul G; Dasgupta A; Chopra S
    Drugs Today (Barc); 2020 Sep; 56(9):583-598. PubMed ID: 33025952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.
    Thabit AK; Crandon JL; Nicolau DP
    Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy.
    Van Bambeke F
    Future Microbiol; 2015; 10(7):1111-23. PubMed ID: 26119479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.